Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SMMT Summit Therapeutics PLC

盘前交易 08-12 09:06:52 EDT

15.12

+0.25

+1.65%

盘前15.40

+0.29+1.89%

08:56 EDT

最高15.73	最低14.68	成交量496.04万
今开15.03	昨收14.87	日振幅7.06%
总市值120.58亿	流通市值23.03亿	总股本7.98亿
成交额7,538万	换手率3.26%	流通股本1.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":15.115,"timestamp":1786478400000,"preClose":14.87,"halted":0,"volume":4960447,"hourTrading":{"tag":"盘前","latestPrice":15.4,"preClose":15.115,"latestTime":"08:56 EDT","volume":6258,"amount":96137.01056400001,"timestamp":1786539406950,"change":0.285,"changeRate":0.018855,"amplitude":0.029772},"delay":0,"changeRate":0.01647612642905185,"floatShares":152343050,"shares":797749602,"eps":-1.117703,"marketStatus":"盘前交易","change":0.245,"latestTime":"08-12 09:06:52 EDT","open":15.03,"high":15.73,"low":14.68,"amount":75376030.908717,"amplitude":0.070612,"askPrice":15.6,"askSize":100,"bidPrice":15.4,"bidSize":60,"shortable":3,"etf":0,"ttmEps":-1.117703,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786541400000},"marketStatusCode":1,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":15.115,"preHourTrading":{"tag":"盘前","latestPrice":15.4,"preClose":15.115,"latestTime":"08:56 EDT","volume":6258,"amount":96137.01056400001,"timestamp":1786539406950,"change":0.285,"changeRate":0.018855,"amplitude":0.029772},"postHourTrading":{"tag":"盘后","latestPrice":15.2,"preClose":15.115,"latestTime":"19:55 EDT","volume":74009,"amount":1120752.6308,"timestamp":1786492521773,"change":0.085,"changeRate":0.005624,"amplitude":0.031095},"volumeRatio":1.6193521125070838,"impliedVol":0.7552,"impliedVolPercentile":0.228},"requestUrl":"/m/hq/s/SMMT/wiki","defaultTab":"wiki","newsList":[{"id":"1182231349","title":"Summit Therapeutics启动膀胱癌药物Ivonescimab全球II/III期Harmoni-Gu1试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1182231349","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182231349?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:09","pubTimestamp":1785928189,"startTime":"0","endTime":"0","summary":"Summit Therapeutics公司宣布，已正式启动一项针对膀胱癌的全球性II/III期临床试验——Harmoni-Gu1研究。该试验旨在评估其候选药物Ivonescimab的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4139","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148778913","title":"异动解读 | Summit Therapeutics夜盘大跌5.54%，第二季度财报发布引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1148778913","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148778913?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:06","pubTimestamp":1784851586,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（SMMT）在今日夜盘交易时段股价大幅下挫5.54%，引发了市场的广泛关注。消息面上，公司于盘后发布了截至2026年6月30日的第二季度及上半年财务业绩与运营进展报告。尽管新闻稿未详细披露具体财务数据，但股价在报告公布后随即出现显著下跌，显示市场对其业绩表现或未来展望可能感到失望。Summit Therapeutics在报告中同步更新了其在核心管线推进及战略布局方面的阶段性进展。投资者将密切关注后续更多的财务细节及管理层解读，以评估此次股价波动的合理性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159318299","title":"Summit Therapeutics 拟通过销售代理发行及出售总价值最高达3.8亿美元的普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1159318299","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159318299?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:51","pubTimestamp":1784839908,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会（SEC）文件披露，Summit Therapeutics 公司宣布了一项重大融资计划。该公司计划通过一家销售代理机构，进行普通股的发行与出售。此次拟发行的股票总价值，最高可达3.8亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156544666","title":"异动解读 | Summit Therapeutics盘后大跌6.03%，第二季度财务业绩发布引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1156544666","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156544666?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:36","pubTimestamp":1784838986,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（SMMT）今日盘后股价大幅下挫6.03%，引发市场广泛关注。消息面上，公司于盘后发布了截至2026年6月30日的第二季度及上半年财务业绩与运营进展报告。尽管新闻稿未详细披露具体财务数据，但股价在报告公布后随即出现显著下跌，显示市场对其业绩表现或未来展望可能感到失望。Summit Therapeutics在报告中同步更新了其在核心管线推进及战略布局方面的阶段性进展。投资者将密切关注后续更多的财务细节及管理层解读，以评估此次股价波动的合理性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116827920","title":"Summit Therapeutics公布2026年第二季度及上半年财务业绩与运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1116827920","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116827920?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:09","pubTimestamp":1784837376,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（以下简称“Summit”）正式披露了截至2026年6月30日的第二季度及上半年的财务数据，并同步更新了公司在运营层面取得的阶段性进展。本次报告不仅呈现了公司在过去几个月的财务健康状况，还勾勒出其在推进核心管线及战略布局方面的关键动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653071107","title":"欧洲车市强势反弹！6月销量创近三年最大涨幅 电动车成“救命稻草”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653071107","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653071107?lang=zh_cn&edition=full","pubTime":"2026-07-23 14:42","pubTimestamp":1784788955,"startTime":"0","endTime":"0","summary":"欧洲6月新车销量增长13%法国和德国是欧洲最大的电动车市场。除波兰外，欧洲其他所有国家的电动车销量均实现增长。今年3月，奇瑞汽车旗下捷途7车型成为英国销量最高的汽车。这些企业目前正面临国内生产成本高企、以及在全球最大汽车市场中国销量低迷的双重压力。欧洲最大汽车制造商大众汽车正陷入迄今最严重的危机之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK4139","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180108436","title":"Arcus Biosciences与Summit Therapeutics达成临床试验合作，评估Casdatifan联合Ivonescimab治疗肾癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1180108436","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180108436?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:32","pubTimestamp":1784752323,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc. (RCUS) 与 Summit Therapeutics PLC (SMMT) 宣布达成一项临床试验合作，旨在评估Casdatifan与Ivonescimab联合疗法在肾癌治疗中的潜力。该合作将探索两种研究性药物的协同作用，为肾细胞癌患者开发新的治疗选择。双方将整合各自的研发资源与专业知识，共同推进此项临床研究，以期加速创新疗法的开发进程。这项合作标志着两家公司在肿瘤免疫治疗领域深化探索，致力于应对未满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","RCUS","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165080744","title":"Ivonescimab联合化疗在HARMONi全球III期研究最新分析中，于西方与亚洲患者中展现一致且良好的总生存期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1165080744","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165080744?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:32","pubTimestamp":1784716350,"startTime":"0","endTime":"0","summary":"在HARMONi全球III期研究的最新分析中，Ivonescimab联合化疗方案在西方患者群体与亚洲患者群体中，均展示出具有一致性且令人鼓舞的总生存期获益。该结果进一步支持了该联合疗法在不同人群中的广泛适用性与积极疗效前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154355492","title":"Summit Therapeutics 联合疗法在亚裔及西方患者中展现积极总生存期趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1154355492","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154355492?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:31","pubTimestamp":1784716281,"startTime":"0","endTime":"0","summary":"Summit Therapeutics 公司宣布，其核心候选药物 Ivonescimab 联合化疗方案，在针对亚洲与西方患者群体的临床研究中，呈现出积极的总生存期趋势。这一进展进一步验证了该联合疗法的潜在疗效，有望为相关患者群体带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180446530","title":"财报前瞻 ｜Summit Therapeutics PLC本季度营收或持平零，机构观点偏审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1180446530","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180446530?lang=zh_cn&edition=full","pubTime":"2026-07-17 00:17","pubTimestamp":1784218621,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC将于2026年07月23日发布财报，市场聚焦其现金消耗与管线里程碑进展，对盈利改善的时间点保持观望。市场一致预期显示，本季度Summit Therapeutics PLC的营收预计为0.00美元，同比为0.00%；预计调整后每股收益为-0.28美元，同比下降195.57%；预计息税前利润为-1.96亿美元，同比下降170.70%。上季度Summit Therapeutics PLC实现营收0.00美元，毛利率数据未披露；归属于母公司股东的净利润为-1.89亿美元，净利率未披露；调整后每股收益为-0.24美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜Summit Therapeutics PLC本季度营收或持平零，机构观点偏审慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1101292791","title":"Summit Therapeutics获50万美元预付款及高达1.045亿美元里程碑款项加分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1101292791","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101292791?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:04","pubTimestamp":1784027068,"startTime":"0","endTime":"0","summary":"Summit Therapeutics公司宣布，将获得一笔50万美元的预付款。此外，该公司还有资格获得总额最高达1.045亿美元的里程碑付款，以及基于销售额的分级特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646635842","title":"英国5月汽车产量同比增长2.7%，结束连续四个月下降势头","url":"https://stock-news.laohu8.com/highlight/detail?id=2646635842","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646635842?lang=zh_cn&edition=full","pubTime":"2026-06-25 07:50","pubTimestamp":1782345000,"startTime":"0","endTime":"0","summary":"英国汽车制造商和贸易商协会周四表示，英国5月份汽车产量同比增长 2.7%，结束了连续四个月的下降势头。　　SMMT的数据显示，英国5月份汽车产量增至51178辆，其中乘用车产量同比增长3.2%至49249辆，商用车产量同比下降7.6%至1929辆。　　上月英国对美国的汽车出口量增长了83.1%，而对欧盟和中国的出口量分别下降了5.2%和14.3%。　　今年前五个月，英国汽车产量下降8.7%，至317779辆。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-25/doc-inieqnay1062058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FSXEmain","FESXmain","SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646842559","title":"受美国出口增长带动 英国汽车产量在5月首次回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2646842559","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646842559?lang=zh_cn&edition=full","pubTime":"2026-06-25 07:48","pubTimestamp":1782344904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154114279","title":"Summit Therapeutics 融资所得将用于 Ivonescimab 研发、营运资金及一般公司用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1154114279","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154114279?lang=zh_cn&edition=full","pubTime":"2026-06-10 04:48","pubTimestamp":1781038091,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC 此次融资筹集的资金，将专项用于其核心在研药物 Ivonescimab 的研发工作、补充公司营运资金，以及满足其他一般性企业用途。此举旨在为公司的关键研发管线提供资金支持，并确保日常运营的财务灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159064563","title":"异动解读 | 临床试验数据存疑引发市场担忧，Summit Therapeutics盘中大跌7.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159064563","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159064563?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:33","pubTimestamp":1780320830,"startTime":"0","endTime":"0","summary":"Summit Therapeutics（SMMT）今日盘中股价大跌7.41%，引起了市场的广泛关注。消息面上，尽管公司及其中国合作伙伴Akeso的实验性抗癌药物ivonescimab在晚期肺癌临床试验中显示出能延长患者生存期的积极效果，但市场对此反应消极。部分分析师指出，该研究仅在中国进行，其疗效能否在更广泛的全球患者群体（如美国和欧洲）中得到验证仍存在疑问。投资者担忧药物未来在这些关键市场的获批前景，这可能是导致股价承压下跌的主要原因。Summit公司通过一项价值高达500亿美元的协议获得了该药物在美、加、欧、日等地区的权益，此次数据的局限性引发了市场对其长期商业潜力的重新评估。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194620744","title":"异动解读 | 临床试验数据虽积极但存疑，Summit Therapeutics盘前大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194620744","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194620744?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:31","pubTimestamp":1780320713,"startTime":"0","endTime":"0","summary":"Summit Therapeutics（SMMT）今日盘前股价大幅下挫5.25%，引起了投资者的密切关注。消息面上，尽管公司及其中国合作伙伴Akeso的实验性抗癌药物ivonescimab在晚期肺癌临床试验中显示出能延长患者生存期的积极效果，但市场对此反应消极。部分分析师指出，该研究仅在中国进行，其疗效能否在更广泛的全球患者群体中得到验证仍存在疑问。投资者担忧药物未来在美国和欧洲等关键市场的获批前景，这可能是导致股价承压下跌的主要原因。Summit公司通过一项价值高达500亿美元的协议获得了该药物在美、加、欧、日等地区的权益，此次数据的局限性引发了市场对其长期商业潜力的重新评估。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637341190","title":"H.C. Wainwright下调Summit评级，默沙东ADC数据引发竞争担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2637341190","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637341190?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:46","pubTimestamp":1779479160,"startTime":"0","endTime":"0","summary":"由于竞争对手默沙东与科伦博泰合作的抗体偶联药物sac-TMT在肺癌治疗中取得积极III期数据，H.C． Wainwright于5月22日将Summit Therapeutics的股票评级从买入下调至中性，并取消了此前23美元的目标价。　　此次下调的核心原因在于，H.C． Wainwright对sac-TMT数据给Summit核心药物ivonescimab带来的竞争压力表示担忧。Summit目前没有任何已上市药物，过去十二个月EBITDA亏损达12.2亿美元，持续处于亏损状态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhtz7330931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145262250","title":"异动解读 | Summit Therapeutics盘中大跌5.01%，H.c.Wainwright下调目标价叠加临床数据利空","url":"https://stock-news.laohu8.com/highlight/detail?id=1145262250","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145262250?lang=zh_cn&edition=full","pubTime":"2026-05-08 01:15","pubTimestamp":1778174117,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  今日盘中股价大跌5.01%，引起了市场关注。消息面上，此次下跌主要受到两方面因素影响。首先，投行H.c.Wainwright近日将公司目标价从30美元下调至23美元，直接打击了市场信心。其次，公司此前披露的HARMONi-3研究中，针对鳞状非小细胞肺癌的中期无进展生存期分析未达到统计学显著性的成功标准，这一利空消息的影响仍在持续发酵。多家机构相继下调目标价，形成了负面共振效应。公司表示，HARMONi-3研究的最终PFS结果预计将于今年下半年发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119497710","title":"异动解读 | Summit Therapeutics盘中大涨5.42%，花旗维持买入评级及ASCO数据预期提振反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1119497710","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119497710?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:54","pubTimestamp":1777902888,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) 今日盘中股价大幅上涨5.42%，引起了市场的广泛关注。消息面上，尽管公司此前因HARMONi-3鳞状非小细胞肺癌中期PFS数据未达统计学显著性而股价受挫，但花旗分析师Yigal Nochomovitz在利空公布后仍维持买入评级及40美元目标价，为市场注入了信心。此外，公司与康方生物合作的依沃西单抗即将在ASCO会议上公布HARMONi-6总生存期数据，市场对后续催化事件存在期待，共同推动了此次超跌反弹。公司表示HARMONi-3最终PFS结果将于下半年发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100864984","title":"Summit Therapeutics公布2026年第一季度财务业绩及运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100864984","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100864984?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:33","pubTimestamp":1777581201,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（纳斯达克代码：SMMT）近日披露了截至2026年3月31日的第一季度财务报告及业务发展动态。\n公司在本季度持续推进核心研发管线，重点聚焦创新疗法的临床开发。管理层在财报中强调了关键项目的里程碑进展，同时概述了战略布局与资金配置情况。\n财务方面，季报详细呈现了营收状况、研发投入及现金流表现。公司表示将保持稳健的财务管控，以支持长期研发目标与商业化准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":0.0985},{"period":"1month","weight":-0.0089},{"period":"3month","weight":-0.1956},{"period":"6month","weight":0.0332},{"period":"1year","weight":-0.465},{"period":"ytd","weight":-0.1358}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Summit Therapeutics Inc.于2013年11月22日在英格兰和威尔士注册成立，特拉华州的一家公司（“New Summit”）已成为该公司的后续发行方。该公司是一家生物制药公司，专注于发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法，旨在提高生活质量，延长潜在寿命，并解决严重的未满足的医疗需求。该公司的候选产品管线的设计目标是成为肿瘤治疗领域中对患者友好的、新时代的标准护理药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.0357},{"month":3,"riseRate":0.454545,"avgChangeRate":0.039344},{"month":4,"riseRate":0.5,"avgChangeRate":0.042597},{"month":5,"riseRate":0.5,"avgChangeRate":0.075963},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.093606},{"month":7,"riseRate":0.583333,"avgChangeRate":0.072153},{"month":8,"riseRate":0.5,"avgChangeRate":0.006989},{"month":9,"riseRate":0.363636,"avgChangeRate":0.075404},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}